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Calcium signalingExperimental evidence shows the importance of the immune system in controlling tumor appearance and
growth. Immunotherapy is deﬁned as the treatment of a disease by inducing, enhancing or suppressing an
immune response. In the context of cancer treatment, it involves breaking tolerance to a cancer-speciﬁc self-
antigen and/or enhancing the existing anti-tumor immune response, be it speciﬁc or not. Part of the complexity
in developing such treatment is that cancers are selected to escape adaptive or innate immune responses. These
escape mechanisms are numerous and they may cumulate in one cancer. Moreover, different cancers of a same
type may present different combinations of escape mechanisms. The limited success of immunotherapeutics in
the clinic as stand-alone products may in part be explained by the fact that most of them only activate one
facet of the immune response. It is important to identify novel methods to broaden the efﬁcacy of immunother-
apeutics. Calcium signaling is central to numerous cellular processes, leading to immune responses, cancer
growth and apoptosis induced by cancer treatments. Calcium signaling in cancer therapy and control will be
integrated to current cancer immunotherapy approaches. This article is part of a Special Issue entitled: Calcium
Signaling in Health and Disease. Guest Editors: Geert Bultynck, Jacques Haiech, Claus W. Heizmann, Joachim
Krebs, and Marc Moreau.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Cancer is one of the most devastating pathologies in terms of epide-
miology and outcome. In the world, 14 million new cases occurred in
2012 with 8 million deaths. Interestingly, there is less variation in mor-
tality than in incidence between more developed and less developed
countries (http://globocan.iarc.fr). This demonstrates that prevention
in the western world plays a signiﬁcant role in identifying cancer pa-
tients but having a larger choice of treatment modalities has a limited
impact on this disease. The social costs of cancer are enormous (200 bil-
lion USD in the US in 2008) and theWorld Health Organization projects
an increase in cancer related deaths from 7.6 million in 2008 to
13.1 million in 2030 worldwide (http://www.who.int/topics/cancer).
Although treatment options are numerous, they all share limited
success and toxicity. An underexploited tool in this arsenal is the use
of the immune system to ﬁght the patient's own cancer. This paradigm
is known as immunotherapy and an important body of preclinical data
shows that all arms of the human immune system are involved [1].
Ample approaches have been or are being evaluated in clinical settings
and in many cases, they have generated disappointing results [2]. Many
reasons can explain these results and the accumulating information
from immunotherapy-based clinical trials demonstrates that thisSignaling inHealth andDisease.
Heizmann, Joachim Krebs, and
ights reserved.approach will best perform when used in combination with additional
anti-cancer treatments [3]. These may either be standard of care or
novel anti-cancer treatments. From this standpoint, calcium signaling
is clearly over-looked in cancer therapy in general and particularly in
the context of an immune intervention targeting cancers. Calcium is
central in many biological processes including the elaboration and the
control of an immune response [4]. Modiﬁcation of calcium signaling
to enhance tumor-targeting immunity could be done at the level of
the innate arm of the immune stimulation. Besides being possibly sufﬁ-
cient to control cancer growth, it is required for proper antigen presen-
tation to the immune system and development of the speciﬁc response
[5]. Calcium signaling also plays an important role in the elaboration of
an adaptive, antigen-speciﬁc, immune response which is thought
crucial in the control of cancer. The latter intervention could act by en-
hancing or by preventing the resorption of the effector response direct-
ed against the cancer or the environment upon which it strives. It may
also act by relieving the cancer-induced immunosuppression.
Enhancing the efﬁcacy of immunotherapy may give this technology
the potential of controlling and/or eliminating tumors on a stand-alone
basis but also to have additive effects on cancer growthwhen usedwith
standard of care therapies [6]. This concept comes from their non-
overlapping modes of action. The former generally involve inhibiting
cell division yielding an intrinsic cell death signalwhile immunotherapy
acts by extrinsic cytotoxic mechanisms driven by immune mediators.
More recently, synergy between the two treatment modalities has
been proposed [7]. Indeed, in addition to their speciﬁc, non-redundant
effects, cell death pathways induced by some chemotherapeutic drugs,
radiotherapy or photodynamic therapy are immunostimulatory and
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the generation of an anamnestic anti-tumor response may impact on
tumor reoccurrence and metastasis. Calcium is involved in all these
steps and controlling itsmetabolismpunctually and/or locally could sig-
niﬁcantly help in the anti-tumor control [8].
2. History
In its broadest deﬁnition, immunotherapy is the treatment of a dis-
ease by inducing, enhancing or dampening an immune response. Immu-
notherapy may therefore be applied to any condition in which an
immune component is involved and ranges from inﬂammation and auto-
immunity, in which the goal is to diminish an exacerbated immune re-
sponse, to chronic infections and cancer where the immune response
must be boosted. The concept that the immune response has a role in
controlling cancer has existed for many years but has only been convinc-
ingly demonstrated recently [1]. This was done by ﬁrst inducing tumors
with a carcinogen in either immunodeﬁcient or immunocompetent
mice. Each tumor was then split in half with one half being grafted in
an immunodeﬁcient animal and the other in an immunocompetent ani-
mal (Fig. 1).
It was observed that cancers taken from immunodeﬁcient animals
grew when transplanted in similarly immunodeﬁcient animals but
that they were rejected when transplanted in immunocompetent ani-
mals. Conversely, cancers arising in immunocompetent animals had
the capacity to grow in either type of grafted mouse. These results
show that spontaneously arising tumors are immunogenic, that the im-
mune system is capable of eliminating them andmore importantly, that
the immune system exerts a selective pressure on the cancer and selects
out cells that have the capacity to evade this immune response. The role
of immune-surveillance in controlling cancer initiation and progression
has also been indisputably demonstrated by the increase frequency of
various types of cancers in immunodeﬁcient mouse strains (reviewed
in [1]). In a more clinically relevant setting, the demonstration that
the intra-tumoral cytotoxic T cell inﬁltrate (CD8+) is correlated with
a favorable outcome of the patient treatment and that it can be used
as a predictive marker shows that the immune response existing in a
patient undeniably plays a role in controlling the cancer's evolution
even in the context of standard of care therapies [9].
The concept that the immune systemmay be used in the treatment
of cancer originates from serendipitous observations made in the late
18th century which associated cancer regression and infections. The
ﬁrst immunotherapeutic intervention per se was developed byWilliam
Coley, in 1893 in which a mixture of killed Streptococcus pyogenes andFig. 1. Cancer immunoediting experiment. See text for details. GraNeisseria marcescens was used to treat several types of cancers [10].
This product was commercialized for 70 years before being classiﬁed
as a “new drug” by the FDA in 1963. This limited its use to clinical trials
that yielded unclear results and production was stopped.
Since this period, important technological advances, a better under-
standing of immune mechanisms and their interaction with cancer has
led to the preclinical and clinical evaluations of numerous compounds
and approaches to harness the patient's immune response to their cancer.
While this ﬁeld is rapidly evolving, to date, only a handful of products are
commercialized and are the backbone of only 3% of cancer therapies. This
is expected to go up to 60% in thenext 10 years and represents a potential
market of 35 billion USD (http://www.reuters.com/article/2013/05/22/
us-cancer-immunotherapy-idUSBRE94L0CF20130522). The oldest ap-
proved cancer immunotherapeutic product still in use is the tuberculosis
vaccine Bacille Calmet–Guérin (BCG) which was approved in 1976 to
treat early, non-invasive bladder cancer [11]. It is believed to act by bind-
ing to urothelial carcinoma cells, causing a modiﬁcation in the cytokine
and chemokine milieu which will attract phagocytes. These latter cells
produce Th1-type cytokines which will orient the immune response to-
ward a more cytotoxic response [12].
3. Deﬁnitions
Immunotherapeutic interventions applied to cancer are generally
classiﬁed as either active or passive (Fig. 2).
The former may be non-speciﬁc and involves a general stimulation
of the immune system achieved with molecules such as cytokines. In
this instance, tumor control may be exerted by innate immune mecha-
nisms and/or the pre-existing antigen-speciﬁc immune response, inde-
pendent of the knowledge of the antigen. At the other end of the
spectrum of active immunotherapy, an immune response directed to
an antigen expressed speciﬁcally or mainly on cancer cells may be
achieved by therapeutic vaccination. The common denominator of this
type of treatment is the exposure of the host's immune system to a
given cancer antigen in a context such that it will stimulate a speciﬁc re-
sponse [13]. An alternative active approach is termed adoptive T cell
transfer (ATCT) (reviewed in [14]). It consists in amplifying ex vivo
patient's tumor inﬁltrating lymphocytes (TILs), or cells from the blood,
in conditions that will enrich for cells that express a T cell receptor
(TCR) recognizing a tumor antigen presented in the context of syngene-
ic major histocompatibility complex (MHC). This procedure has been
further modiﬁed by engineering ex vivo ampliﬁed effector T cells with
retroviruses or lentiviruses to make them express a receptor speciﬁc
for an antigen [15].phs below describe tumor volume (Y axis) vs time (X axis).
Fig. 2. Cancer immunotherapy interventions. See text for details.
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nize proteins necessary for the development of cancer and that do not
stimulate the host's immune response [16]. Besides blocking the inter-
action between the ligand and its receptor, some of these antibodies
mediate their beneﬁcial effect via immune mechanisms such as Anti-
body Dependent Cell Cytotoxicity (ADCC) or Complement Dependent
Cytotoxicity (CDC).
A very promising approach is the association between passive and
active immunotherapy which creates a new class of agents termed
“checkpoint blockers” [17]. It involves the use of antibodies, as in pas-
sive immunotherapy, that act onmolecules expressed by cells of the im-
mune system that play a role in the maintenance of the immune
response, similar to active immunotherapy. Each of these approaches
will be detailed in following sections.
4. Cytokines
The advent of recombinant DNA technology had a profound impact
on immunotherapy. The possibility to clone genes encoding cytokines,
have them expressed in bacteria or eukaryotic cells to produce large
quantities of protein that can be puriﬁed in well characterized lots
gave the possibility to test a number of cytokines in the clinic. This
lead to the approval of interferon alpha (IFNα) to treat hairy cell leuke-
mia in 1986 going along the then popular idea that most cancers were
virally induced [18]. Interleukin-2 (IL-2)was tested during the same pe-
riod in the clinic and was approved in 1996 to treat metastatic melano-
ma based on a clinical trial in which 6% of patients had a complete
response to treatment and 10% a partial response [19]. It also has been
developed and is used to treat metastatic renal cell carcinoma [20].
Since then, little improvement has been made for these pathologies
and IL-2 remains one of the only treatment options for late stage dis-
ease. Other cytokines are currently being evaluated in clinical trials in
oncology, such as IL-7, IL-12, IL-15, IL-21 andGM-CSF and clinical results
are pending [21].
5. Cancer vaccines
Although a few proteins were known to be overexpressed by cancer
cells in the 70s (carcinoembryonic antigen, α-phetoprotein, mucin-1,
prostate speciﬁc antigen, etc.), theywere essentially used as biomarkers
[22]. It is in 1991 that it was ﬁrst demonstrated that cancer cells could
express antigens with an otherwise restricted expression pattern andthat they could be recognized by cytotoxic T lymphocytes [23]. This
led to the identiﬁcation of numerous other tumor antigens and opened
the door to cancer vaccines (reviewed in [24]).
In essence, it involves generating or recalling an immune response to
a target protein known to be represented mainly on the cancer cells
with limited distribution in normal tissues. Classical as well as innova-
tive vaccine technologies have been used to test this family of products,
each having their strong points and weaknesses (Table 1).
These range from HLA-restricted peptides combined to various im-
munological adjuvants to intramuscular injection of plasmid DNA ac-
companied with electroporation of the injected area. Although the
pre-clinical data, generally obtained inmousemodels, using these high-
ly appealing approaches are convincing, the clinical data have been dis-
appointing in terms of patient's beneﬁt [25]. Indeed, the confounded
data accumulating over the last 20 years on cancer vaccines, either
used as stand-alone or in combination with standard therapies, yield a
picture in which generally 20% of patients respond [26]. This has been
partly explained by two important observations that have impacted
on the landscape of cancer immunotherapy. The ﬁrst of these observa-
tions comes from the immunomonitoring performed during clinical tri-
als on vaccinated patients. The obvious goal of this work is to identify or
correlate the effector immunemechanisms with the patient's response.
In spite of a signiﬁcant investment in terms of the assays used and their
standardization, to date, no obvious correlation can be done between
the immune response generated by the vaccination and the outcome
of the disease. The absence of tumor control in face of a demonstrable
immune response suggests that the tumor-induced immunosuppres-
sion overrides the immune response in amajority of cases [27]. It there-
fore appears crucial to relieve this immunosuppression to enhance the
efﬁcacy of cancer vaccines. The second point stemming from these ob-
servations is that in many instances, the design of the clinical trials are
based on what has been done for small molecules in which case the ef-
fect on tumor cells is fast and the impact on the tumor mass is rapid.
Many clinical trials evaluating cancer vaccines have failed to meet
their primary endpoint because cancer evolution was measured over a
time period too short for a full-blown immune response to set in and/
or to have a signiﬁcant effect on the tumor mass. Moreover, long-term
follow-up of vaccinated patients shows a dichotomy between survival
and tumor volume [28,29]. This suggests the non-mutually exclusive
possibilities that vaccination switches back the tumor evolution to the
equilibrium phase of cancer immunoediting or that the local immune
response precludes measuring changes in tumor volumes by current
Table 1
General technologies developed for cancer vaccines. Dendritic cells may be autologous or heterologous. The cytokines used in their production impact on the response generated. DNA
vaccines may be electroporated in humans after injection. Tumor cells may be autologous or heterologous and/or genetically manipulated to express cytokines. Vectors encompass bac-
teria, viruses, retroviruses, and yeasts. Others include RNA vaccination, peptide strings, and fusion protein.
Source: Pharma etrack.
Vaccine Proportion in clinical trials Pros Cons
Dendritic cells 17% –One approved product
–Differentiation in absence of immunosuppression
–Possibility to orient differentiation
–Difﬁcult to produce
DNA 4% –Easy to produce
–No size limit for expressed gene
–Poor immune response in human
Tumor cell 10% –Many antigens may be targeted at once –Difﬁcult to produce
Vector based 5% –No adjuvant needed –May be impacted by standard of care
Proteins 17% –No HLA restriction
–Easy to produce
–Requires adjuvant
Peptide 14% –Easy to produce –HLA restriction
–Requires adjuvant
Others 33%
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hindsight on clinical results have been central in changing the ﬁeld's
point of view. It is also becoming clear that not all patients may beneﬁt
from an immunotherapeutic intervention and that early clinical trials
including a dedicated biomarker identiﬁcation approach and patients
stratiﬁcation allow the identiﬁcation of a responding patient subpopula-
tion [30]. This is exempliﬁed by the START Phase III clinical trial ran by
Merck-Serono in which the product L-BLP25 (tecemotide) has failed
to meet its primary endpoint of improving overall survival in late
stage Non-small Cell Lung Cancer (NSCLC) [31]. Nonetheless, Merck is
pursuing the development of this product in the START2 phase III trial
based on thedata fromanexploratory analysis of a predeﬁned subgroup
of patients in the START trial who received tecemotide after concurrent
chemoradiotherapy (CRT: combination of chemotherapy and radiother-
apy given at the same time). These patients achieved a median OS
of 30.8 months versus 20.6 months for patients treated with placebo
(n = 806; HR: 0.78; 95% CI: 0.64–0.95; p = 0.016). This illustrates
that it is important that future clinical trials are designed and adapted
to properly evaluate the ideal conditions of use of immunotherapeutics
and identify the responding patient population. Calcium signaling has
never been exploited in this context and may offer an edge in this
endeavor.
6. Adoptive cell transfer
The demonstration that T cells are present in cancer patients and
that they react to cancer antigens has also justiﬁed an original approach
in which in vitro-ampliﬁed tumor antigen-speciﬁc T cells taken from
resected tumor or patient's blood are re-infused in the same patient.
Coined adoptive T cell transfer, and in opposition to classical vaccina-
tion, it consists in the ampliﬁcation of a functional T cell population out-
side of the immunosuppressed environment of the patient [32]. As for
most personalizedmedicine approaches, the development and eventual
commercialization of this type of product represent a challenge worth
being taken up in face of the promising clinical beneﬁt which shows ob-
jective cancer regression in more than 50% of melanoma patients and
efﬁcacy in other solid and hematological cancers [33,34]. Moreover,
the capacity to genetically modify these cells with a receptor speciﬁc
to a tumor antigen prior to reinfusion enhances the efﬁcacy of this ap-
proach and broadens the number of indications in which it can be
used. T cells can be modiﬁed to express either the T cell receptor that
is themost represented in the TILs, the one isolated from the T cell pop-
ulation responding to a speciﬁc antigen in vitro orwith chimeric antigen
receptors (CARs). This latter technology involves transducing in vitro-
ampliﬁed T cells with a lentivirus expressing the fused variable portions
of a monoclonal antibody heavy and light chains (scFv) linked to a
transmembrane domain itself fused to the intracellular signaling
domain of the CD3ζ protein [35]. It alleviates the T cells from MHCrestriction and the associated mechanisms needed for proper T cell
stimulation such as antigen processing, presentation and co-
stimulation thatmay bemodiﬁed in the tumor context. Rather, it targets
the transduced population to a molecule overexpressed on the cancer.
The ﬁrst generation of CAR constructs was ﬁrst shown to work in vitro
in the late 80s by Z Eshnar [36]. These constructs were then tested in a
number of indications in the clinic and saw their efﬁcacy limited to
some partial responses, stable diseases and few remissions only in glio-
blastoma and B cell lymphoma. Since that time, second and third gener-
ation CARs have been developed by adding, respectively, one or
multiple additional signaling domains from various co-stimulatorymol-
ecules [37,38]. These are currently being tested in the clinic and
preclinic respectively and are showing promising results with some
complete remissions. However, severe toxic effects were seen with sec-
ond and third generation CARs and cautionmust be takenwhen admin-
istering these therapeutic entities [39]. Target-speciﬁc, off-cancer effect
may in part be the culprit for this toxicity but cytokines released by this
relatively long-lived cell populationmay also account for these deleteri-
ous effects. Possible solutions to this problem is to increase the speciﬁc-
ity of the chimeric receptors to limit their effect to cancer cells and/or
the inclusion of a suicide gene in the modiﬁed T cells so that a pro-
drugmay be administered and this population eliminated upon adverse
events. Finally, given the personalized nature of this method, the future
of thisﬁeld lies in the development of productionmethodswhichwould
make it available to more patients and ideally, commercializable at a
competitive cost [33].
One successful cancer immunotherapy product which partly meets
these criteria and based on adoptive transfer of autologous cells is
Provenge also referred to as Sipuleucel-T [40]. It has been approved
for commercialization by the Food and Drug Administration (FDA) in
2010 and by the EuropeanMedical Agency (EMA) in 2013 for the treat-
ment of minimally symptomatic, castration-resistant androgen inde-
pendent metastatic prostate cancer. It consists of getting the patient's
dendritic cells (DC) by leukapheresis, stimulating them in vitro by ex-
posing them to a recombinant human protein made of a fusion of the
prostatic acid phosphatase protein, serving as the prostate cancer-
speciﬁc antigen cancer, and the cytokine granulocyte-macrophage colo-
ny stimulating factor (GM-CSF) needed to stimulate theDC. The cells are
then injected in the patients. The clinical beneﬁt is statistically signiﬁ-
cant in this pathology and pushes themedian survival by 4.1 months al-
though the precise mode of action remains to be determined. It is
interesting to note that the ﬁrst Biological License Application (BLA)
submitted in 2007 was turned down by the FDA as the organization
asked for more data but also expressed concerns about the complexity
and standardization of themanufacturing process. A number of compa-
nies are currently developing similar products with various proprietary
DC maturation protocols that should impact on the nature of the im-
mune response generated in the patients after reinfusion [41].
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The development and the capacity to produce monoclonal antibod-
ies was another crucial technological step that played a very important
role in passive immunotherapy [42]. The hybridoma technology was
ﬁrst described in 1973 by Schwaber and Cohen and involves fusing a
mouse myeloma having lost its capacity to produce antibodies with
normal B cells from immunized mice and selecting a clone producing
an antibody speciﬁc for a target antigen [43]. It became rapidly obvious
that injectingmouse antibodies in humans induced an anti-mouse anti-
body response and formation of immune complexes causing rapid elim-
ination of the injected protein and poor effector functions [44]. To
circumvent this, DNA sequences coding for the variable parts of the
mouse antibody were grafted to the sequences coding for the human
constant region generating chimeric antibodies. This was further im-
proved by Greg Winter in 1988 when he modiﬁed the regions ﬂanking
the variable sequences with conserved human sequences generating
what are now called humanized antibodies [45].
The ﬁrst commercialized antibody in oncology, used in the treat-
ment of non-Hodgkin lymphoma in 1997, is the anti-CD20 antibody Ri-
tuximab. Over the following 16 years, 13 other antibodies interacting
with a total of 8molecular targets have gained FDAapproval in oncology
(Table 2) [16].
Bevacizumab binds VEGF-A, blocks its interaction with its receptor
and inhibits neo-vascularization. It is the only antibody which binds a
soluble target [46]. All the other antibodies used in oncology exert
their anti-tumor function by various, non-mutually exclusive mecha-
nisms. By binding to CD20 or CD52 in the treatment of non-Hodgkin
lymphoma or chronic lymphocytic leukemia, some antibodies directly
induce apoptosis [47]. This may be a direct effect on the targeted recep-
tor or by its cross-linking due to the capacity of the antibody to bind, via
its constant region, to the Fcγ receptor, present on NK cells and cells
from the granulocytic/myeloid lineage. Most of the antibodies in oncol-
ogy are of the IgG1 isotype and can therefore bridge the target cells with
the Fcγ receptor andmediate ADCC, and/or antibody-dependent phago-
cytosis [48,49]. By engineering the Fc portion ormodifying the glycosyl-
ation pattern, the interactionwith the FcR can bedecreased or enhanced
impacting on its lytic activity [49]. Somemodiﬁcations being tested also
have an effect on the serumhalf-life of the antibody [50]. Controlling the
pharmacokinetics may prove to be beneﬁcial economically, with dose-
sparing, dose-saving, longer clinical effect, or allow mitigating toxicity
with faster clearance.
Concurrently, many other formats are being developed and evaluat-
ed [51]. Smaller molecules made of the variable region of antibodies
may be used. The Fab consists in the variable region and its proximal
constant domain of the heavy and light chains. It is monovalent and
has a very short half-life in the circulation. To circumvent this problem,
antibodies with a paratope selected to recognize two antigens have
been developed and are currently in phase II trials [52]. Another way
to ensure dual speciﬁcity is the use of scFv which may be covalently orTable 2
FDA approved antibodies.
Antibody Target Tumors
Cetuximab EGFR Colon ﬂead and neck
Panitumumab EGFR Colon
Trastuzumab HER2 Breast gastric
Pertuzumab HER2 Breast colon
Bevacizumab VEGF NSCLC glioblastoma kidney
Ipilimumab CTLA-4 Melanoma
Rituximab CD20 NHL chronic lymphocytic leukemia
Ofatumumab CD20 Chronic lymphocytic leukemia
Ibritumomab CD20 Low grade or follicular B cell NHL
Tositumomab CD20 Low grade or follicular B cell NHL
Alemtuzumab CD52 Chronic Lymphocytic leukemia
Brentuximab CD30 Hodgkin's lymphoma
Gemtuzumab CD33 Acute myelogenous leukemianon-covalently-linked heavy and light variable parts of an antibody
[53]. This type of construct may be further modiﬁed to recognize two
or more different antigenic structures as diabodies, tribodies etc. BiTE
(Bi-speciﬁc T cell engager) and DART (dual afﬁnity re-targeting) for-
mats are currently being evaluated in the clinic [54,55]. They bridge T
cells to cancer cells by recognizing the CD3 receptor on the former
and the CD19 molecule on the lymphoma. Conversely, in some in-
stances such as c-Met, it may be important to avoid cross-linking of
the target receptor and single chain Ig is preferable [56].
At their inception, antibodies were described as the magic bullet ca-
pable of delivering payloads such as cytokines or cytotoxic molecules at
speciﬁc sites. The time taken to decipher the proper chemistry to link
antibodies to other molecules was longer than expected but Antibody-
Drug-Conjugates (ADC) are now in the clinic with some products
being commercialized [57]. The two products are conjugates between
antibodies (brentuximab and trastuzumab) and cytotoxics (microtu-
bule antagonists (monomethyl irostatin and maytansin, respectively)).
The former is engineered as to deliver its payload after being cleaved
by cathepsin B in the lysosomewhile the latter acts onemost of the an-
tibody has been degraded [58,59]. The clinical success of these ADCs
leads to the development of numerous coupling and delivery ap-
proaches that are being evaluated [60].
8. Checkpoint agents
As mentioned above, many patients with a functional immune re-
sponse against their cancer show little clinical beneﬁt indicating that
the growing cancer has evolved ways to evade the immune response.
One approach taken to alleviate the immune system from this immuno-
suppression was to developmonoclonal antibodies which block regula-
tors of the immune response. These checkpoints are used by the
immune system to dampen the response once T cells have been stimu-
lated. Two such molecules have been targeted by monoclonal antibod-
ies and have generated highly encouraging clinical results. Ipilimumab
is an antibody directed to CTLA-4 and is commercialized under the
name of Yervoy. CTLA-4 is normally expressed by activated T cells
with CD80 and CD86 expressed on antigen expressing cells and limits
T cell response. By blocking this interaction, ipilimumab ampliﬁes the
immune response to the cancer. It also acts by killing regulatory T cells
[61]. Itwas approved for the treatment ofmelanomaon the basis of clin-
ical results in which 23% of patients receiving ipilimumab survived
3 years versus 10% [62]. The other checkpoint molecule to be targeted
is called Programmed Death-1 (PD1) as well as its ligands PDL-1 and
PDL-2. Antibodies blocking their interaction are currently being evaluat-
ed in the clinic [63]. Because CTLA-4 is expressed shortly after T cell
stimulation and that PD-1's expression occurs later, it was estimated
that the combination of both antibodies would have a greater beneﬁt.
This is seen in a recent clinical trial inwhich 53% of advancedmelanoma
patients responded to the treatment and 18% had a complete response.
All responders had at least 80% reductions by week 12 and lasted more
than one year [64]. The enthusiasm generated by these impressive re-
sults has motivated numerous clinical trials in which checkpoint
blockers are being evaluated either alone or in combination and in nu-
merous indications (Table 3).
While the clinical beneﬁt is undeniable, caution must be taken be-
cause serious side effects have been notice in these trials [65]. Nonethe-
less, these results are important steps in the ﬁght against cancer and for
the ﬁeld of immunotherapy.
9. Calcium and immunotherapy
Calcium signaling plays an important role in almost all biological
processes including the immune response. The immune system undeni-
ably plays a role in controlling cancer and recent clinical results show
that we are getting closer to successfully use this powerful tool. Howev-
er, it is relatively difﬁcult to target a speciﬁc calcium-relatedmechanism
Table 3
Current clinical development of PD-1/PD-1 L1 checkpoint blockers. Five other products
have been identiﬁed but have not reached clinical stage.
Source: Citeline.
Drug Company Target Cancer type Status
Nivolumab
BMS-936558
MDX-1106
ONO-4538
BMS/Ono PD-1 Renal Phase III
NSCLC Phase III
Melanoma Phase III
Prostate Phase II
Colorectal Phase II
Ovarian Phase II
Solid Phase 1
CML Phase 1
Myeloma Phase 1
NHL Phase 1
Hodgkin's Phase 1
Liver Phase 1
Lambrolizumab
MK-3475
Merck PD-1 Melanoma Phase II
NSCLC Phase II
Solid Phase 1
Breast Phase 1
Head and neck Phase 1
Renal Phase 1
Bladder Phase 1
Urethral Phase 1
Hematological Preclinical
RG-7446
MPDL-3280A
Roche PD-1 LI NSCLC Phase II
Melanoma Phase 1
Stomach Phase 1
Colorectal Phase 1
Renal Phase 1
Solid Phase 1
Pidilizumab
CT-011
CureTech PD-1 B-cell lymphoma Phase II
Colorectal Phase II
Melanoma Phase II
NHL Phase II
MDX-1105
BMS-936559
BMS PD-1 LI Breast Phase 1
Colorectal Phase 1
Renal Phase 1
NSCLC Phase 1
Melanoma Phase 1
Ovarian Phase 1
Stomach Phase 1
Pancreatic Phase 1
MEDI-4736 AstraZeneka PD-1 LI Melanoma Phase 1
Renal Phase 1
NSCLC Phase 1
Colorectal Phase 1
MS B-0010718C Merck KGaA PD-1 LI Solid Phase 1
2339R. Rooke / Biochimica et Biophysica Acta 1843 (2014) 2334–2340without tampering with the calcium metabolism involved in other sys-
tems. Aswe are gaining knowledge on the interactions between the im-
mune system and cancers, the steps in which calcium signaling are
involved will become more obvious. One can therefore envisage using
this additional tool to better modulate the immune response in favor
of the patient. It is interesting to note that the T cell receptor-induced
calcium response is reduced in PD-1 expressing cells [66]. Finally, one
way by which calciummay be used is as a predictive or prognostic bio-
marker. The ﬁeld remains unexplored to date.
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